Mangalam Drugs and Organics Ltd Share Price Today - Mangalam Drugs and Organics Ltd Stock Price Live NSE/BSE

Mangalam Drugs and Organics Ltd

NSE: MANGALAM BSE: 532637

₹31.89

(-3.97%)

Fri, 13 Mar 2026, 06:34 pm

MTF 5xInvest in Mangalam Drugs and Organics Ltd with 5x Leverage Buy with MTF

Market Cap525.02M

PE Ratio0

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Mangalam Drugs and Organics Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
51.44
Net Profit
6.72
P/B
0.83
Sector P/E
32.90
P/E
17.46
EV/EBITDA
5.81
Debt/Equity (Industry)
0.23
Interest Cover (Industry)
10.03
ROCE (Industry)
12.82
RONW (Industry)
12.23
ROE
4.84
ROCE
8.07
Debt/Equity
0.73
EPS (TTM)
0
Dividend Yield
0
Book Value
76.13
Interest Cover
1.32

Analysis

all

Pros

Mangalam Drugs & Organics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Mangalam Drugs & Organics has been profitable on average in the past, therefore cash runway is not a concern.
Mangalam Drugs & Organics has been profitable on average in the past, therefore cash runway is not a concern.
Debt is well covered by operating cash flow (30.1%, greater than 20% of total debt).
Debt is covered by short term assets, assets are 1.7x debt.

Cons

Unable to calculate sustainability of dividends as Mangalam Drugs & Organics has not reported any payouts.
Unable to evaluate Mangalam Drugs & Organics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Mangalam Drugs & Organics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Mangalam Drugs & Organics is making a loss, therefore interest payments are not well covered by earnings.
Mangalam Drugs & Organics's level of debt (65.1%) compared to net worth is high (greater than 40%).

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	35.64	50.30	50.30	50.30	50.30
FII	0.13	0.11	0.53	0.47	0.11
DII	0.00	0.00	0.00	0.00	0.00
Public	64.22	49.58	49.16	49.23	49.58
Government	0	0	0	0	0

Technical Analysis

RSI

46.81

MACD

-0.80

50 DMA

35.65

200 DMA

59.71

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	50.69	41.25	35.17	31.81	25.73	22.37	12.93
Fibonacci	41.25	37.65	35.42	31.81	28.21	25.98	22.37
Camarilla	31.68	30.81	29.95	31.81	28.21	27.35	26.48

Pivots Level: Classic

+18.88

50.69

+9.44

41.25

+3.35

35.17

31.81

Pivot Point

LTP: 31.71

-6.09

25.73

-9.44

22.37

-18.88

12.93

Moving Average

SMAEMA

Period

Value

10-EMA
31.69
20-EMA
32.08
30-EMA
32.78
50-EMA
34.60
100-EMA
41.56
200-EMA
55.07

Announcement Date	Purpose	Action	Ex Date
15 Jan 2026	board-meetings	Quarterly Results
20 Nov 2025	board-meetings	Quarterly Results
13 Nov 2025	board-meetings	Quarterly Results
07 Sept 2025	agm
12 Jul 2025	egm
04 Sept 2024	agm
18 Sept 2023	agm
05 Sept 2022	agm
03 Sept 2021	agm
17 Aug 2018	agm	Annual General Meeting	19 Sept 2018

Mangalam Drugs and Organics Ltd

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd

Lupin Ltd

Divis Laboratories Ltd

Mangalam Drugs and Organics Ltd About

Mangalam Drugs and Organics engaged in the manufacture and sale of Active Pharmaceutical Ingredients (API) for various therapeutic segments viz. Anti Malaria, Anti-Retrovirat, Anti-Hypertensive etc.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1972

Headquarters

CEO

Govardhan M Dhoot

Employees

Contact

Website

http://www.mangalamdrugs.com

contactus@mangalamdrugs.com

Phone

91-22-22616200/6300/8787

Location

3rd Floor Rupam Building, 239 P D Mello Road, Mumbai, Maharashtra, 400001

Year	History
2003	WHO-GMP approval was received for Amodiaquine Hydrochloride and Amodiaquine U.S.P. The company was awarded ISO-9000-2000 Management System Certificate from DNV.
2005	Mangalam Drugs and Organics Ltd filed a prospectus with Securities Exchange Board of India to raise Rs 14.3 crore through a public issue. Shares of Mangalam Drugs & Organics Ltd made their debut on the Bombay Stock Exchange at Rs 30.
2006	The Company recommended a Final Dividend of Re 0.20 ps (2%) per Equity Share.
2009	Mr. Mukul Sukhani was appointed as Additional Director on the Board of the Company.
2014	Mrs Meenal Sukhani was appointed as Additional Director on the Board of the Company. The registered office of the company was shifted from Princess Street Near Flyover Bridge, Marine Lines, Mumbai to 3rd Floor, Rupam Building, 237, P. D. Mello Road, Mumbai - 400001, Maharashtra.

Client Name	Order Side	QTY	Avg Price	Date
NEO APEX VENTURE LLP	Sell	105753	38.01	03 Feb 2026
NEO APEX VENTURE LLP	Sell	350000	37.9	03 Feb 2026
NEO APEX VENTURE LLP	Buy	455753	32.68	02 Feb 2026
JYOTIPRASAD TAPARIA	Sell	150000	42.64	13 Jan 2026
SANJAY KUMAR SAINI	Sell	95000	40.65	13 Jan 2026
SHIVKUMAR DAMANI	Sell	81999	40.61	12 Jan 2026
ASHUTOSH TAPARIA	Sell	200000	40.61	12 Jan 2026
SANJAY KUMAR SAINI	Buy	95000	38.77	09 Jan 2026
EPITOME TRADING AND INVESTMENTS	Sell	134064	38.77	09 Jan 2026
EPITOME TRADING AND INVESTMENTS	Buy	100000	36.84	08 Jan 2026

Mangalam Drugs and Organics Ltd News

Mangalam Drugs Board Approves Key Leadership Changes

Mangalam Drugs & Organics accepts independent director resignation, appoints new CFO Jeevan M. Dalvi, and approves Dr. Praveen Saxena's re-appointment for second term.

06 Feb 2026

stocks

Mangalam Drugs Reports Q3 FY26 Loss, Key Resignations

Mangalam Drugs & Organics posted consolidated net loss of ₹983.55 lakhs in Q3 FY26 vs profit of ₹128.68 lakhs in Q3 FY25. CFO and Company Secretary resigned citing health and career reasons.

15 Jan 2026

co actions results

Mangalam Drugs Clarifies No Material Info on Price Move

Mangalam Drugs & Organics responds to BSE surveillance query, stating no material information pending disclosure and attributing price movements to market sentiment.

07 Jan 2026

stocks

Mangalam Drugs CFO Ajay Samant Resigns

Mangalam Drugs & Organics announces CFO Ajay Samant's resignation effective March 31, 2025, due to attainment of retirement age as per company guidelines.

24 Dec 2025

stocks

Mangalam Drugs And Organics Secures Rs 15 Crore Order

Mangalam Drugs And Organics has received an order worth Rs 15 crore. The order represents approximately 26% of the company's current market capitalization of Rs 57 crore.

26 Nov 2025

stock

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800